Las Vegas, NV -- (SBWIRE) -- 12/19/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Targacept , Inc. (NASDAQ:TRGT), Kandi Technologies Group Inc (NASDAQ:KNDI), Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX), Cell Therapeutics Inc (NASDAQ:CTIC)
Targacept , Inc. (NASDAQ:TRGT) opened the session at $3.89, trading in a range of $3.75 - $3.90, and closed at $3.85. The stock showed a negative performance of -1.53% in the last trading session. The stock traded on a volume of 1.23 million shares and the average volume of the stock remained 303,023 shares. Targacept, Inc., a biopharmaceutical company, engages in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system. Its product candidates include TC-5619 that is in Phase IIb clinical trial for the treatment of negative symptoms and cognitive dysfunction in schizophrenia; TC-5214 to treat overactive bladder; and TC-1734, which is in Phase IIb clinical trial for the treatment of mild to moderate Alzheimer?s disease.
Will TRGT Get Buyers Even After The Recent Rally? Find Out Here
Kandi Technologies Group Inc (NASDAQ:KNDI) traded 1.23 million shares in the last business day while the average volume of the stock remained 967,907 shares. The stock showed a negative movement of -1.76% to end at $7.83. The 52 week range of the stock remained $3.37 - $9.20. Kandi Technologies Group, Inc., through its subsidiaries, engages in the design, development, manufacture, and commercialization of various vehicles. It offers electrical vehicles, all-terrain vehicles, go-karts, and specialized automobiles; and utility vehicles, three-wheeled motorcycle, refitted cars, super-mini-cars, and various auto generators. Kandi Technologies Group, Inc. sells its products through trading companies in North America, Europe, and China.
Has KNDI Found The Bottom And Ready To Gain Momentum? Find Out Here
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) reported 1.21 million shares were exchanged during the last trade, while the average volume is about 1.12 million shares. The stock escalated +2.06% and finished the day at $1.98. The beta of the stock is recorded at 0.46. Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders.
Why Should Investors Buy CPRX After The Recent Gain? Just Go Here and Find Out
Cell Therapeutics Inc (NASDAQ:CTIC) the stock advanced +1.75% and finished the session at $1.74. Traded with volume of 1.19 million shares in the prior session and the average volume of the stock remained 3.16 million shares. Cell Therapeutics, Inc. acquires, develops, and commercializes treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
Will CTIC Continue To Move Higher? Find Out Here
We screen the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Once we find the 'Next Hot Penny Stock' with Monster Upside Potential we immediately Email it to you in our detailed VIP Report so you can Beat Rest of the Crowd!!
Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way.
VipstockReports.com newsletters and website: The disclaimer is to be read entirely and fully understood before using our website, or joining our newsletter email list. Never invest into a stock discussed on this website or the Vipstockalerts.com newsletter unless you can afford to lose your entire investment. Please consult with a certified financial advisor before making any investment decisions.
VipStockReports.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your financial advisor before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies profiled on the VipstockReports.com web site and/or newsletter involve a high degree of volatility and risk, and all investors should know that they may lose a portion of or all of their investment if they decide to purchase any stocks.
Read Full Disclaimer at: http://www.vipstockreports.com/disclaimer/
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)